Trump’s tariff court defeats and EU rift—plus Iran-linked oil volatility—what markets fear next

A cluster of developments on May 8, 2026 points to a widening policy-and-market feedback loop in the US and Europe. Multiple outlets report that Trump’s latest tariff plans have been struck down again by federal courts, reinforcing skepticism toward executive overreach. At the same time, reporting highlights a growing political feud between Donald Trump and Germany’s Friedrich Merz that is complicating the EU’s push to finalize a US trade deal before new tariffs arrive. Separately, the US political and regulatory environment is tightening: President Trump has reportedly signed off on a plan to fire FDA Commissioner Marty Makary after clashes over vaping, abortion, and drug policy, while US health officials are also said to have explored banning some widely used antidepressants. Strategically, the tariff rulings and EU-US friction suggest that trade policy is becoming a contested instrument of statecraft rather than a stable negotiating framework. The immediate winners are likely legal and institutional checks—courts and EU negotiators—while the losers are deal momentum and predictability for cross-border supply chains. The Merz feud matters because Germany is central to EU bargaining leverage, and any perceived US unpredictability can shift EU negotiating posture toward defensive concessions or slower ratification timelines. Meanwhile, the FDA and potential antidepressant ban discussions raise the stakes for domestic regulatory credibility, which can spill into investor risk premia for healthcare and consumer-facing compliance-heavy sectors. Market implications cut across trade, energy, and risk sentiment. Tariff uncertainty typically pressures industrials and autos; one article flags Canada’s car industry facing a “double whammy” from US tariffs and declining EV support, with Honda’s troubles adding to negative sentiment. Energy markets appear more jittery: reporting notes irrational oil-price swings tied to Trump’s comments, while another piece describes a sharp drop in upstream oil-and-gas deal values amid uncertainty, signaling delayed investment decisions. Financial derivatives linked to “potato-linked” contracts reportedly surged more than 700% in weeks despite European oversupply, illustrating how speculative trading is finding proxies for volatility tied to the Iran war; this aligns with broader signals of rising Hormuz tensions and AI-sector positioning pressures. What to watch next is whether the US executive branch can repackage tariff measures into court-resistant forms and whether the EU accelerates or renegotiates its US trade deal timetable. Trigger points include additional court rulings, any escalation in Hormuz-related risk premiums, and concrete regulatory actions following the FDA commissioner firing plan and antidepressant ban exploration. On the market side, watch for widening credit spreads in tariff-exposed industrial supply chains, oil volatility measures, and continued growth in speculative commodity-linked contracts as a barometer of risk appetite. For de-escalation, the key would be evidence of EU-US deal progress that reduces the probability of fresh tariff waves before the next policy window.

Geopolitical Implications

• 01

  Transatlantic trade is becoming litigation-driven, reducing predictability and increasing policy whiplash risk for supply chains.

• 02

  Germany’s central role in EU bargaining means personal disputes with the US president can slow or harden EU trade outcomes.

• 03

  US domestic regulatory politics can reshape compliance expectations and investor perceptions of institutional stability.

• 04

  Middle East energy risk via Hormuz is amplifying volatility and potentially feeding inflation and risk premia globally.

Key Signals

• —New court outcomes and whether tariff measures are rewritten to survive judicial scrutiny.
• —EU negotiation milestones and any acceleration or renegotiation of the US trade deal timeline.
• —Procedural steps and formal actions tied to the FDA commissioner firing plan.
• —Concrete movement on antidepressant restrictions and healthcare market reaction.
• —Oil volatility, shipping/insurance risk premia, and derivative pricing linked to Iran/Hormuz.